Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study

Radiation Oncology

Joseph M Herman⁵  John L Cameron⁵  Christopher L Wolfgang⁵  Richard D Schulick⁵  John H Donohue⁷  Michael G Haddock³  Jordan M Winter¹  Jessica Zhou⁸  Ralph H Hruban⁴  Dan Laheru²  Timothy M Pawlik⁵  Sumita Bhatia³  Charles C Hsu⁶  Robert C Miller³  Amol K Narang⁸ 

[1] Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Radiation Oncology, The Mayo Clinic, Rochester, MN, USA;Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;The Sol Goldman Pancreatic Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA;Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA;Department of Surgery, The Mayo Clinic, Rochester, MN, USA;Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

关键词: resectable;    chemoradiation;    adjuvant;    carcinoma;    ampullary;   

Others  :  1223889
DOI  :  10.1186/1748-717X-6-126

 received in 2011-06-16, accepted in 2011-09-28,  发布年份 2011

【 摘 要 】

Background

The role of adjuvant chemoradiation therapy for ampullary carcinoma is unknown. Previous literature suggests that certain populations with high risk factors for recurrence may benefit from adjuvant chemoradiation. We combined the experience of two institutions to better delineate which patients may benefit from adjuvant chemoradiation.

Methods

Patients who underwent curative surgery for ampullary carcinoma at the Johns Hopkins Hospital (n = 290; 1992-2007) and at the Mayo Clinic (n = 130; 1977-2005) were reviewed. Patients with <60 days of follow-up, metastatic disease at surgery, or insufficient pathologic data were excluded. The final combined study consisted of 186 patients (n = 104 Johns Hopkins, n = 82 Mayo). Most patients received 5-FU based chemoradiation with conformal radiation. Cox proportional hazards models were used for survival analysis.

Results

Median overall-survival was 39.9 months with 2- and 5-year survival rates of 62.4% and 39.1%. On univariate analysis, adverse prognostic factors for overall survival included T3/T4 stage disease (RR = 1.86, p = 0.002), node positive status (RR = 3.18, p < 0.001), and poor histological grade (RR = 1.69, p = 0.011). Patients who received adjuvant chemoradiation (n = 66) vs. surgery alone (n = 120) showed a higher rate of T3/T4 stage disease (57.6% vs. 30.8%, P < 0.001), lymph node involvement (72.7% vs. 30.0%, P < 0.001), and close or positive margins (4.6% vs. 0.0%, P = 0.019). Five year survival rates among node negative and node positive patients were 58.7% and 18.4% respectively. When compared with surgery alone, use of adjuvant chemoradiation improved survival among node positive patients (mOS 32.1 vs. 15.7 mos, 5 yr OS: 27.5% vs. 5.9%; RR = 0.47, P = 0.004). After adjusting for adverse prognostic factors on multivariate analysis, patients treated with adjuvant chemoradiation demonstrated a significant survival benefit (RR = 0.40, P < 0.001). Disease relapse occurred in 37.1% of all patients, most commonly metastatic disease in the liver or peritoneum.

Conclusions

Node-positive patients with resected ampullary adenocarcinoma may benefit from 5-FU based adjuvant chemoradiation. Since a significant proportion of patients develop metastatic disease, there is a need for more effective systemic treatment.

【 授权许可】

   
2011 Narang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Pathology, complication and outcomes. Ann Surg 1997, 226:248-260.
• [2]Bouvet M, Gamagami RA, Gilpin EA, Romeo O, Sasson A, Easter DW, Moossa AR: Factors influencing survival after resection for periampullary neoplasms. Am J Surg 2000, 180:13-17.
• [3]Stephens J, Kuhn J, O'Brien J, Preskitt J, Derrick H, Fisher T, Fuller R, Lieberman Z: Surgical morbidity, mortality, and long term survival in patients with pancreatic cancer following pancreaticoduodenectomy. Am J Surg 1997, 174:600-604.
• [4]Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
• [5]Matory YL, Gaynor J, Brennan M: Carcinoma of the ampulla of Vator. Surg Gynecol Obstet 1993, 177:366-370.
• [6]Monson JR, Donohue JH, McEntee GP, McIlrath DC, van Heerden JA, Shorter RG, Nagorney DM, Ilstrup DM: Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991, 126:353-357.
• [7]Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Adenocarcinoma of the ampulla of Vater: a 28-year experience. Ann Surg 1997, 225:590-600.
• [8]De Castro SM, Kuhlmann KF, van Heek NT, Busch OR, Offerhaus GJ, van Gulik TM, Obertop H, Gouma DJ: Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 2004, 8:775-784.
• [9]Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF: Factors predictive of survival in ampullary carcinoma. Ann Surg 1998, 228:87-94.
• [10]Brown KM, Tompkins AJ, Yong S, et al.: Pancreaticoduodenectomy is curative in the majority of patients with node negative ampullary cancer. Arch Surg 2005, 140:529-533.
• [11]El-Ghazzawy AG, Wade TP, Virgo KS, Johnson FE: Recent experience with the cancer of the ampulla of Vater in a national hospital group. Am Surg 1995, 61:607-611.
• [12]Klempnauer J, Ridder GJ, Pichlmayr R: Prognostic factors after resection of ampullary carcinoma: Multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Br J Surg 1995, 82:1686-1691.
• [13]Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987, 59:2006-2010.
• [14]Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5- Fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230:776-784.
• [15]Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW: Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 2008, 70:735-743.
• [16]Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S: Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2006, 66:514-519.
• [17]Zhou J, Hsu CC, Winter JM, Pawlik TM, Laheru D, Hughes MA, Donehower R, Wolfgang C, Akbar U, Schulick R, Cameron J, Herman JM: Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiotherapy and Oncology 2009, 92:244-248.
• [18]Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, Schulick RD, Cameron JL, Pawlik TM, Herman JM: Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with adenocarcinoma. Int J Radiat Oncol Biol Phys, in press.
• [19]Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM: Clinicopathologic analysis for ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010, 14:379-387.
• [20]Kopelson G: Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983, 9:911-915.
• [21]Kopelson G, Galdabini J, Warshaw AL, Gunderson LL: Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: Implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1981, 7:413-417.
• [22]Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, Verbeek PC, de Wit LT, Gouma DJ: Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995, 117:247-253.
• [23]Neoptolemos JP, Talbot IC, Shaw DC: Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness. Cancer 1988, 61:1403-1407.
• [24]Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T: Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999, 134:526-532.
• [25]Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA: Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998, 227:821-831.
• [26]Duffy JP, Hines OJ, Liu JH, Ko CY, Cortina G, Isacoff WH, Nguyen H, Leonardi M, Tompkins RK, Reber HA: Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003, 138:941-948.
• [27]Hsu HP, Yang TM, Hsieh YH: Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007, 14:50-60.
• [28]Delcore R Jr, Connor CS, Thomas JH, Friesen SR, Hermreck AS: Significance of tumor spread in adenocarcinoma of the ampulla of Vater. Am J Surg 1989, 158:593-596.
• [29]Shutze WP, Sack J, Aldrete JS: Long-term follow-up of 24 patients undergoing radical resection for ampullary carcinoma, 1953 to 1988. Cancer 1990, 66:1717-1720.
• [30]O'Connell JB, Maggard MA, Manunga J Jr, Tomlinson JS, Reber HA, Ko CY, Hines OJ: Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Onc 2008, 15:1820-1827.
• [31]Willett CG, Warshaw AL, Convery K, Compton CC: Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet 1993, 176:33-38.
• [32]Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ: Adjuvant chemoradiotherapy for ''unfavorable'' carcinoma of the ampulla of Vater: Preliminary report. Arch Surg 2001, 136:65-69.
• [33]Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, Rosato EF: Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 2000, 47:945-953.
• [34]Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 2007, 297:267-277.
• [35]Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95:1685-1695.
• [36]Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mcdonald A, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Coxon FY, Lacaine F, Middleton MR, Ghaneh P, Bassi C, Halloran C, Olah A, Rawcliffe CL, Büchler MW: Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater [abstract]. J Clin Oncol 2011., 29abstr LBA4006
• [37]Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 14:1273-1281.